Related Experiment Video
Updated: Jun 5, 2026
08:04
Analyzing Platelet Subpopulations by Multi-color Flow Cytometry
Published on: June 10, 2025
Cardiovascular effects of platelet-activating factor.
M R Holland1, T M McIntyre, G A Zimmerman
1Nora Eccles Harrison Cardiovascular Research and Training Institute USA; Departments of Internal Medicine and Biochemistry, University of Utah, Salt Lake City, UT 84112, USA.
Trends in Cardiovascular Medicine
|January 18, 2011
Summary
Platelet-activating factor (PAF) is a key mediator in inflammation and thrombosis. PAF receptor antagonists show therapeutic promise for life-threatening conditions like shock and reperfusion injury.
Area of Science:
- Biochemistry
- Immunology
- Vascular Biology
Background:
- Platelet-activating factor (PAF) is a phospholipid with diverse biological actions beyond platelet activation.
- PAF acts as a mediator in normal inflammatory and thrombotic responses.
- Dysregulated PAF production contributes to vascular injury and hemodynamic disturbances.
Purpose of the Study:
- To review the multifaceted roles of PAF in physiological and pathological processes.
- To highlight PAF's involvement in clinical syndromes such as shock, infarction, and reperfusion injury.
- To discuss the therapeutic potential of PAF receptor antagonists.
Main Methods:
- Literature review of studies on PAF synthesis, actions, and clinical relevance.
- Analysis of evidence implicating PAF in inflammatory and thrombotic disorders.
- Evaluation of preclinical and clinical data on PAF receptor antagonists.
Main Results:
- PAF exhibits a wide range of functions, including potent proinflammatory effects.
- Excessive PAF production is linked to significant vascular injury and hemodynamic derangements.
- PAF plays a role in critical conditions like shock, myocardial infarction, and reperfusion injury.
Conclusions:
- PAF is a crucial mediator in inflammatory and thrombotic processes.
- PAF receptor antagonists represent a promising therapeutic strategy for managing severe vascular disorders.
- Targeting PAF offers potential for treating life-threatening conditions.
Related Concept Videos
01:22Formation of the Platelet Plug
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:18Structure and Function of Platelets
The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000 platelets, with...
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000 platelets, with...
01:16Clot Retraction and Fibrinolysis
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
01:30Peripheral Artery Disease I: Introduction
Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...